News & Events about Atai Life Sciences Nv.
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (atai or the Company), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, ...
- This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101 - KUR-101 was well tolerated and demonstrated analgesic activity in two experimental pain models - An assessment of the respiratory impact of KUR-101 was ...
NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (atai), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the Fellowship Fund) at Massachusetts General Hospital (MGH) Center ...
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates PR Newswire PALM BEACH, FL, Nov. 14, 2022 PALM BEACH, FL, Nov. 14, 2022...
Business Wire
2 months ago
The Women in Psychedelics Network (WIPN or Network), a network of professionals from all corners of the psychedelic industry strengthening womens voices and providing opportunities to move mental health solutions forward, today announced atai Life Sciences N.V. (NASDAQ: ATAI) (atai), a...